Suggested remit: To evaluate the benefits and costs of leriglitazone within its marketing authorisation for treating andrenoleukodystrophy for national commissioning by NHS England.
Status Proposed
Process HST

Provisional Schedule

Scoping workshop 03 November 2021 (14:00)

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 September 2021 - 07 October 2021 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
23 September 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of leriglitazone for andrenoleukodystrophy. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that is developing leriglitazone, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently, the consultation on the draft scope has closed, and the workshop arranged for Wednesday 03 November 2021 has been cancelled. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause If you have any comments or concerns, please contact the project manager for this appraisal Emily Richards on 44 (0)161 413 4070 or via email on

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance